Serina Therapeutics (NYSEAMERICAN:SER) Upgraded at BTIG Research

Serina Therapeutics (NYSEAMERICAN:SER) was upgraded by investment analysts at BTIG Research to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Serina Therapeutics Stock Down 1.0%

Shares of Serina Therapeutics stock opened at $1.90 on Wednesday. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24. Serina Therapeutics has a twelve month low of $1.22 and a twelve month high of $7.92. The company has a 50-day simple moving average of $1.84. The stock has a market cap of $28.50 million, a price-to-earnings ratio of -0.95 and a beta of 1.11.

Serina Therapeutics (NYSEAMERICAN:SER) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.